Since cancer cells-derived PD-L1 EVs play a role in suppressing the activity of immune cells in tumor and consequently immune evasion, a number of preclinical studies investigated potential therapies based on the inhibition of biogenesis and secretion of PD-L1 EVs by cancer cells [67,68]. This evidence concerns the gene CD274 and cancer.